RAV12

RAV12 is a chimeric IgG1 monoclonal antibody that specifically recognizes RAAG12, a primate-restricted N-linked carbohydrate antigen (glycotope) highly expressed on the surface of many human adenocarcinomas, especially those of gastrointestinal origin such as colorectal, gastric, and pancreatic cancers. The antibody binds with high affinity to RAAG12 and exhibits cytotoxic activity in vitro via an oncotic cell death mechanism. In preclinical models, RAV12 demonstrated potent antitumor activity against multiple gastrointestinal tumor xenografts. Its mechanisms include direct cytotoxicity through induction of oncosis (cell swelling and lysis), mediation of antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cell killing, and alteration of survival signaling pathways in tumor cells. Clinical trials showed preliminary evidence of anti-tumor activity but also revealed dose-limiting toxicities such as abdominal pain/diarrhea and elevated liver function tests; these were partially mitigated by fractionated dosing regimens[3][5][6][7][8][10]. Development was discontinued due to safety profile concerns.

Other names

monoclonal antibody RAV12